$RDGL News

Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites

Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™

Vivos Inc Updates Human Therapy Progress in India

Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals

Vivos Issued U.S. Patent No. 12,521,452 B2 Titled "Radiotherapy Gel and Method of Preparing the Same." By USPTO

Vivos Issued U.S. Patent No. 12,521,452 B2 Titled "Radiotherapy Gel and Method of Preparing the Same." By USPTO

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

Vivos Inc Summarizes Progress in its Animal Therapy Division

Vivos Inc Summarzes Preogress in its Animal Therapy Division

Vivos Inc. Issues Shareholder Update Letter

Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics

Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®

Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India

Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India

Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy

Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization

Sleep Apnea Economic Burden in U.S. Exceeds $150B Annually--Vivos' Novel Solution Can Help

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA